{"id":"zostavax-concomitant","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine works by introducing a weakened form of the varicella-zoster virus to the body, which triggers an immune response and helps to build immunity against future infections. The immune response is then boosted by the presence of the virus, allowing the body to recognize and attack the virus more effectively.","oneSentence":"ZOSTAVAX is a live attenuated vaccine that stimulates an immune response against the varicella-zoster virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:35.615Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults 50 years of age and older"}]},"trialDetails":[{"nctId":"NCT02519855","phase":"PHASE3","title":"Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-11","conditions":"Herpes Zoster","enrollment":882},{"nctId":"NCT00535730","phase":"PHASE3","title":"ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Herpes Zoster, Pneumococcal Infection","enrollment":473},{"nctId":"NCT00231816","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Herpes Zoster","enrollment":763}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["V211"],"phase":"phase_3","status":"active","brandName":"ZOSTAVAX™ (concomitant)","genericName":"ZOSTAVAX™ (concomitant)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ZOSTAVAX is a live attenuated vaccine that stimulates an immune response against the varicella-zoster virus. Used for Prevention of herpes zoster (shingles) in adults 50 years of age and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}